Cancer immunotherapy and nanomedicine

Pharmaceutical Research

Volumn 28, Issue 2, 2011, Pages 200-214

  Sheng, Wei Yun ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

adjuvant; cancer immunotherapy; cancer vaccine; nano; tumor immunoediting

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; LIPOSOME; NANOPARTICLE; OBLIMERSEN; PEPTIDE VACCINE; PLATINUM; PROTEIN E6; PROTEIN E7; PROVENGE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR AGONIST; WART VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; APOPTOSIS; B CELL LYMPHOMA; BILE DUCT CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENCAPSULATION; HUMAN; IMMUNOGENICITY; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG METASTASIS; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NANOMEDICINE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OVARY CANCER; OVARY TUMOR; PANCREAS CARCINOMA; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; THYROID MEDULLARY CARCINOMA; TUMOR REJECTION; UTERINE CERVIX CANCER;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG CARRIERS; GENOMICS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MICE; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 79952486562     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0258-8     Document Type: Review

References (163)

1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-11. (Pubitemid 32391043)
2. Whiteside TL, Miescher S, MacDonald HR, Von Fliedner V. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods. 1986;90:221-33. (Pubitemid 16089014)
3. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60. (Pubitemid 38680426)
4. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-48. (Pubitemid 39094044)
5. Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol. 2009;9:470-81.
6. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
7. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz). 2006;54:323-33. (Pubitemid 44627669)
8. Ohta M, Mitomi T, Kimura M, Habu S, Katsuki M. Anomalies in transgenic mice carrying the human interleukin-2 gene. Tokai J Exp Clin Med. 1990;15:307-15.
9. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD- 1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634-43. (Pubitemid 34257540)
10. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-49.
11. Kimura M, Yoshida Y, Narita M, Takenaga K, Takenouchi T, Yamaguchi T, et al. Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus. Int J Cancer. 1999;82:549-55. (Pubitemid 29343455)
12. Kim HM, Kang JS, Lim J, Kim JY, Kim YJ, Lee SJ, et al. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res. 2009;32:781-7.
13. Triest JA, Grignon DJ, Cher ML, Kocheril SV, Montecillo EJ, Talati B, et al. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin Cancer Res. 1998;4:2009-14. (Pubitemid 28369188)
14. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307-19. (Pubitemid 30191694)
15. McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med Oncol. 2009;26 Suppl 1:13-7.
16. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-57. (Pubitemid 46218728)
17. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, et al. Interleukin-2 administration alters the CD4+FOXP3+ Tcell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 2007;67:7487-94. (Pubitemid 47206578)
18. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16:11-20.
19. Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, Yagita H, et al. IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J Immunol. 2006;176:6347-55.
20. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008;26:2034-9.
21. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. 1997;57:4557-63. (Pubitemid 27441061)
22. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res. 2006;12:4265-73.
23. Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008;14:3462-9.
24. Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL- 18. J Transl Med. 2009;7:104.
25. Gidlund M, Orn A, Wigzell H, Senik A, Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature. 1978;273:759-61. (Pubitemid 8357090)
26. Fridman WH, Gresser I, Bandu MT, Aguet M, Neauport-Sautes C. Interferon enhances the expression of Fc gamma receptors. J Immunol. 1980;124:2436-41. (Pubitemid 10113344)
27. Fradelizi D, Gresser I. Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med. 1982;155:1610-22. (Pubitemid 12074202)
28. Gresser I, Bourali C. Exogenous interferon and inducers of interferon in the treatment Balb-c mice inoculated with RC19 tumour cells. Nature. 1969;223:844-5.
29. Gresser I, Bourali C. Antitumor effects of interferon preparations in mice. J Natl Cancer Inst. 1970;45:365-76.
30. Gresser I, Bourali-Maury C. Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastasis in mice. Nat New Biol. 1972;236:78-9.
31. Hersey P, Hasic E, MacDonald M, Edwards A, Spurling A, Coates AS, et al. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer. 1985;51:815-26. (Pubitemid 15056995)
32. Rinehart JJ, Young D, Laforge J, Colborn D, Neidhart JA. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects. Cancer Res. 1987;47:2481-5. (Pubitemid 17099217)
33. Foon KA, Roth MS, Bunn Jr PA. Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin Oncol. 1986;13:35-42. (Pubitemid 17208248)
34. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, O'Fallon JR, et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol. 1984;2:1002-5. (Pubitemid 14026256)
35. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-7.
36. Markman M, Belinson J, Webster K, Zanotti K, Morrison B, Jacobs B, et al. Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. Oncology. 2004;66:343-6. (Pubitemid 39194354)
37. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007;13:4456-66. (Pubitemid 47219714)
38. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol. 1995;17:71-7.
39. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res. 2000;60:1111-6. (Pubitemid 30129553)
40. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res. 2000;6:2268-78. (Pubitemid 30399193)
41. Wall L, Burke F, Barton C, Smyth J, Balkwill F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res. 2003;9:2487-96. (Pubitemid 36842088)
42. Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 1998;58:3660-7. (Pubitemid 28376566)
43. Singal DP, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer. 1996;68:629-36. (Pubitemid 26414525)
44. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001;7:1159-62. (Pubitemid 33010027)
45. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, et al. A phase II study of GM-CSF and rIFNgamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009;113:210-5.
46. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000;82:1138-44. (Pubitemid 30128869)
47. Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A, et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer. 2006;16:1522-8. (Pubitemid 44060374)
48. Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/ paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol. 2008;109:174-81.
49. Chen JT, Hasumi K, Masubuchi K. Interferon-alpha, interferon-gamma and sizofiran in the adjuvant therapy in ovarian cancer-a preliminary trial. Biotherapy. 1992;5:275-80. (Pubitemid 23024372)
50. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, et al. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol. 2004;191:1598-605. (Pubitemid 39491185)
51. Liu G, Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology. 2007;122:149-56. (Pubitemid 47389958)
52. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Tolllike receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005;309:1380-4. (Pubitemid 41209366)
53. Tabiasco J, Devevre E, Rufer N, Salaun B, Cerottini JC, Speiser D, et al. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol. 2006;177:8708-13. (Pubitemid 44893836)
54. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia. 2007;21:53-60. (Pubitemid 44921834)
55. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007;13:6168-74. (Pubitemid 350075077)
56. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006;29:558-68. (Pubitemid 44395280)
57. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol. 2003;149 Suppl 66:53-6. (Pubitemid 38064520)
58. Lee CH, Wu CL, Shiau AL. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res. 2008;14:1905-12.
59. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859-68.
60. Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med. 2009;7:63.
61. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. 2006;8:60-6. (Pubitemid 43154452)
62. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4:249-58. (Pubitemid 38478660)
63. Pan X, Chen L, Liu S, Yang X, Gao JX, Lee RJ. Antitumor activity of G3139 lipid nanoparticles (LNPs). Mol Pharm. 2009;6:211-20.
64. Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol. 2008;195:21-7.
65. Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med. 1989;170:511-26. (Pubitemid 19204278)
66. Munn DH, Cheung NK. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colonystimulating factor. J Exp Med. 1990;172:231-7. (Pubitemid 20217264)
67. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin. 2005;26:1-9. (Pubitemid 40093233)
68. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100:690-7. (Pubitemid 34832980)
69. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004;23:172-81. (Pubitemid 39505086)
70. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 2000;23:255-66. (Pubitemid 30165175)
71. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 2002;8:1028-37. (Pubitemid 34517636)
72. http://www-bimas.cit.nih.gov/molbio/hla-bind/index.shtml.
73. http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm.
74. http://bioinformatics.uams.edu/mirror/propred1/.
75. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85-100. (Pubitemid 29490747)
76. Salit RB, Kast WM, Velders MP. Ins and outs of clinical trials with peptide-based vaccines. Front Biosci. 2002;7:e204-13.
77. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112:26-34.
78. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159-64. (Pubitemid 47538111)
79. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond). 2008;3:343-55. (Pubitemid 351827311)
80. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22:2406-12. (Pubitemid 38757337)
81. Hamdy S,MolaviO,MaZ,HaddadiA,AlshamsanA, GobtiZ, et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cellmediated anti-tumor immunity. Vaccine. 2008;26:5046-57.
82. Sinyakov MS, Dror M, Lublin-Tennenbaum T, Salzberg S, Margel S, Avtalion RR. Nano- and microparticles as adjuvants in vaccine design: success and failure is related to host natural antibodies. Vaccine. 2006;24:6534-41. (Pubitemid 44511861)
83. Park JS, Koh YS, Bang JY, Jeong YI, Lee JJ. Antitumor effect of all-trans retinoic acid-encapsulated nanoparticles of methoxy poly(ethylene glycol)-conjugated chitosan against CT-26 colon carcinoma in vitro. J Pharm Sci. 2008;97:4011-9.
84. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, Kayamuro H, et al. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine. 2008;26:1303-13.
85. Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Yamamoto M, Kohga K, et al. EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol Immunother. 2010;59:759-67.
86. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96:3102-8.
87. Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 2002;62:6952-8. (Pubitemid 35424086)
88. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-7. (Pubitemid 28144091)
89. Roden RB, Monie A, Wu TC. Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med. 2007;7:490-503. (Pubitemid 47244894)
90. Chua BY, Eriksson EM, Brown LE, ZengW, Gowans EJ, Torresi J, et al. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine. 2008;26:4866-75.
91. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol. 2002;169:4905-12. (Pubitemid 35217155)
92. Hosmalin A, Andrieu M, Loing E, Desoutter JF, Hanau D, Gras-Masse H. A. utry-Varsat, and J.G. Guillet. Lipopeptide presentation pathway in dendritic cells. Immunol Lett. 2001;79:97-100.
93. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Tolllike receptor 6 heterodimer. Immunity. 2009;31:873-84.
94. Le Gal FA, Prevost-Blondel A, Lengagne R, Bossus M, Farace F, Chaboissier A, et al. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer. 2002;98:221-7. (Pubitemid 34150806)
95. Xu DH, Zhou CH, Xia YP, Qiu ZY, Wu YZ, Jia ZC, et al. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin. 2007;28:695-702.
96. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-8.
97. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356:152-4.
98. Ulmer JB,Donnelly JJ, Parker SE, RhodesGH, Felgner PL,Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745-9. (Pubitemid 23114660)
99. Liu MA. DNA vaccines: a review. J Intern Med. 2003;253:402-10. (Pubitemid 36418924)
100. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 2000;19:764-78.
101. Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology. 1996;89:59-67. (Pubitemid 26284039)
102. Leachman SA, Tigelaar RE, Shlyankevich M, Slade MD, Irwin M, Chang E, et al. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J Virol. 2000;74:8700-8. (Pubitemid 30666720)
103. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5:387-91. (Pubitemid 29180575)
104. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108:669-78. (Pubitemid 32906195)
105. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol. 2006;144:41-7.
106. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-32. (Pubitemid 28144092)
107. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther. 2003;7:498-505. (Pubitemid 36553419)
108. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. B.A. van, T.M. Liles, E.G. Engleman, and R. Levy. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-26.
109. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, et al. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol. 2003;22:651-6.
110. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-70.
111. Kwon YJ, James E, Shastri N, Frechet JM. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA. 2005;102:18264-8.
112. Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother. 2007;30:378-95.
113. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul. 2007;1:1-9.
114. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991;59:2978-86.
115. Nellore RV, Pande PG, Young D, Bhagat HR. Evaluation of biodegradable microspheres as vaccine adjuvant for hepatitis B surface antigen. J Parenter Sci Technol. 1992;46:176-80.
116. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun. 1997;65:1716-21. (Pubitemid 27193591)
117. Newman KD, Sosnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by Poly(d, l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci. 1998;87:1421-7.
118. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5:496-504.
119. Grant EP, Rock KL. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J Immunol. 1992;148:13-8.
120. Segal AW, Wills EJ, Richmond JE, Slavin G, Black CD, Gregoriadis G. Morphological observations on the cellular and subcellular destination of intravenously administered liposomes. Br J Exp Pathol. 1974;55:320-7.
121. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother. 2008;57:517-30. (Pubitemid 351170535)
122. Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala. rao@na.amedd.army.mil. Adv Drug Deliv Rev. 2000;41:171-88. (Pubitemid 30122957)
123. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-5. (Pubitemid 24196166)
124. Bevan MJ. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med. 1995;182:639-41.
125. Cui Z, Han SJ, Huang L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res. 2004;21:1018-25. (Pubitemid 38870153)
126. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother. 2005;54:1180-90. (Pubitemid 41416950)
127. Walker C, Selby M, Erickson A, Cataldo D, Valensi JP, Van Nest GV. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA. 1992;89:7915-8.
128. Chen W, Carbone FR, McCluskey J. Electroporation and commercial liposomes efficiently deliver soluble protein into the MHC class I presentation pathway. Priming in vitro and in vivo for class I-restricted recognition of soluble antigen. J Immunol Methods. 1993;160:49-57.
129. Tan Y, Whitmore M, Li S, Frederik P, Huang L. LPD nanoparticles-novel nonviral vector for efficient gene delivery. Methods Mol Med. 2002;69:73-81.
130. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry. 1996;35:1027-36. (Pubitemid 26034590)
131. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 1997;4:891-900.
132. Tan Y, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther. 1999;10:2153-61. (Pubitemid 29416295)
133. Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo Jr LD, Huang L. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther. 2003;7:640-8. (Pubitemid 36626244)
134. Leone P, Janson CG, Bilaniuk L, Wang Z, Sorgi F, Huang L, et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol. 2000;48:27-38. (Pubitemid 30432428)
135. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo Jr LD, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol. 2006;23:385-95. (Pubitemid 44630022)
136. Tan Y, Liu F, Li Z, Li S, Huang L. Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. Mol Ther. 2001;3:673-82. (Pubitemid 32509864)
137. Bhowmick S, Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert Opin Drug Deliv. 2008;5:789-803.
138. Whitemore M, Li S, Huang L. Liposome vectors for in vivo gene delivery. Curr Protoc Hum Genet. Chapter 12:Unit 12.8 (2001).
139. Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol. 2007;44:3672-81.
140. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-46. (Pubitemid 40322250)
141. Lai YH, Wang C. Delivery strategies of melanoma vaccines: an overview. Expert Opin Drug Deliv. 2008;5:979-1001.
142. McNeela EA, Mills KH. Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliv Rev. 2001;51:43-54. (Pubitemid 32763071)
143. Tritto E, Mosca F, De GE. Mechanism of action of licensed vaccine adjuvants. Vaccine. 2009;27:3331-4.
144. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19:2673-80. (Pubitemid 32234288)
145. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110:103-11. (Pubitemid 46986423)
146. Alving CR. Antibodies to lipids and liposomes: immunology and safety. J Liposome Res. 2006;16:157-66. (Pubitemid 44358989)
147. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-7. (Pubitemid 36842552)
148. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol. 2003;170:2523-30. (Pubitemid 36245642)
149. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA. 2003;100:3392-7. (Pubitemid 36356594)
150. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001;61:3689-97. (Pubitemid 32694981)
151. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. E.P. van, F. Ciccosanti, M. Piacentini, L. Zitvogel, and G. Kroemer. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54-61.
152. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026-30.
153. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009;183:137-44.
154. Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010;59:137-48.
155. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8. (Pubitemid 46348738)
156. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155:1063-74. (Pubitemid 12142723)
157. Silva GA. Nanotechnology approaches to crossing the bloodbrain barrier and drug delivery to the CNS. BMC Neurosci. 2008;9 Suppl 3:S4.
158. Ito A, Honda H, Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother. 2006;55:320-8.
159. van Landeghem FK, Maier-Hauff K, Jordan A, Hoffmann KT, Gneveckow U, Scholz R, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials. 2009;30:52-7.
160. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
161. Duncan R, Connors TA, Meada H. Drug targeting in cancer therapy: the magic bullet, what next? J Drug Target. 1996;3:317-9. (Pubitemid 26059822)
162. Chari RV. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev. 1998;31:89-104. (Pubitemid 28191877)
163. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84. (Pubitemid 30122932)